Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Shares Traded Last Trade
  10.00 5.13% 205.00 796,415 14:12:53
Bid Price Offer Price High Price Low Price Open Price
200.00 210.00 205.00 196.00 199.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.19 -56.50 -72.78 334
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:57 O 250,000 200.00 GBX

Amryt Pharma (AMYT) Latest News (3)

More Amryt Pharma News
Amryt Pharma Investors    Amryt Pharma Takeover Rumours

Amryt Pharma (AMYT) Discussions and Chat

Amryt Pharma Forums and Chat

Date Time Title Posts
20/1/202123:09Amryt Pharma6,240
04/6/202006:58Amryt Pharma14
29/9/201908:53Amryt Pharma125
22/5/201918:19AMRYT Bio-Pharma R&D12

Add a New Thread

Amryt Pharma (AMYT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-20 17:15:00200.00250,000500,000.00O
2021-01-20 17:15:00200.0075,000150,000.00O
2021-01-20 16:35:58206.0013,00026,780.00O
2021-01-20 16:29:39207.752,8505,920.88O
2021-01-20 16:26:14206.005,00010,300.00O
View all Amryt Pharma trades in real-time

Amryt Pharma (AMYT) Top Chat Posts

Amryt Pharma Daily Update: Amryt Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AMYT. The last closing price for Amryt Pharma was 195p.
Amryt Pharma Plc has a 4 week average price of 187p and a 12 week average price of 187p.
The 1 year high share price is 245p while the 1 year low share price is currently 82.50p.
There are currently 162,801,593 shares in issue and the average daily traded volume is 26,084 shares. The market capitalisation of Amryt Pharma Plc is £333,743,265.65.
ultrasharp: Unfortunately a stream of good news recently is not propelling the AMYT share price upwards. Hopefully the weekend might bring some newspaper tips. I've got 6000 AMYT shares and I'll probably sell a 1000 next week and buy more GPM with the proceeds as I'm very bullish on gold. That will leave me with 5000 AMYT shares which has always been my intended core holding and hope that AMYT turns out to be a slow burner and gradually rise, or better still receives a takeover bid. PS Bitcoin has been a better performing asset than gold since COVID-19 came on the scene, especially recently, on inflation fears due to all the government borrowing and money printing going on worldwide. Unfortunately I know nothing about cryptocurrencies. ATB PAPILLON
ultrasharp: We have to face facts. There is no enthusiasm for AMYT on Nasdaq despite a stream of good news since the listing on Nasdaq in July. We saw the negative impact Nasdaq had on the AMYT share price back on the 9th September after the good news RNS had propelled the AMYT share price upwards on AIM. I'm firmly of the opinion that the AMYT share price would now be close to 300p, instead of the current 205p, if AMYT hadn't listed on Nasdaq bearing in mind the very positive RNS newsflow since 9th September. I can only assume that American investors bad memories of Aegerion and Novelion has soured their enthusiasm for AMYT. ATB PAPILLON
ultrasharp: If the AMYT share price doesn't respond positively to Thursday's Q2 figures I'm tempted to give up in disgust because the AMYT share price seems incapable of rising, especially on Nasdaq, in response to good news. ATB PAPILLON
ultrasharp: Disappointing share price rise on AIM today after such a good RNS. Generally poor market conditions don't help. Hopefully AMYT will perform better on Nasdaq this afternoon. Definitely not a time to sell. I believe the AMYT share price will continue to climb over the few weeks. Don't forget more good news on the way including likely good Q2 figures issued next week. ATB PAPILLON
ultrasharp: Closed @ US$13 on Nasdaq. At the current exchange rate of 1.2968 that's equal to 200.5p per AMYT share on AIM. BLOODY Nasdaq!! In fairness to Nasdaq and American PI's the share price did rise significantly on AIM in anticipation of the Nasdaq listing so perhaps today's closing price on Nasdaq is a fair reflection of Amryt's current value. In retrospect the AMYT share price on AIM immediately prior to the Nasdaq listing was significantly overbought and far too high! I think we'll have to await further news on the AP101 front, primarily the official verdict on the efficacy of the treatment, as highlighted by diamondstar, or an acquisition as mentioned by Alphabravo321, before we see further progress in the AMYT share price Hope I'm wrong as I'm still holding 5000 shares. ATB PAPILLON
papillon: Opened down @ 12.47 on Nasdaq. 5 tiny trades so far all @ 12.47. The biggest is for 78 ADS's. A couple for just 1 ADS and another 2 for just 4 ADS's. What the hell is behind those trades? Some think that a single share trade on AIM is an MM signal, but I'm not wholly convinced of that! Listing on Nasdaq has been a disaster for the AMYT share price on AIM. I had great hopes in the run up to the listing on Nasdaq, but my hopes have been dashed. For whatever reason there seems to be no enthusiasm for Amryt on Nasdaq, despite the lofty analyst share price target prices. Yet Krystal Bloody Biotech (KRYS)appears to be a Nasdaq darling and has raised loads of cash without trashing it's share price hTTps://
papillon: The ADS's closed at US$13.50 on Nasdaq. Dividing by 5 and then the current exchange rate of 1.30 gives an equivalent price in sterling of 207.70p per AMYT share so I can envisage another fall in the AMYT share price on AIM tomorrow, but probably not a big as 10p. Could be worth a top up tomorrow? I suspect that the price of the ADS's is being dragged down on Nasdaq by small former Novelion shareholders selling the AMYT shares they received in exchange for their shares in Novelion. If I remember correctly former Novelion shareholders only received around 16m shares between them (circa 10% of the new AMYT shares in issue) so that could account for all the small 100 ADS sales since AMYT listed on Nasdaq back in July. Perhaps today's high volume on Nasdaq signifies most of those small ex Novelion shareholders, who were awaiting the AP101 results, have decided to cash in today? Hopefully that selling stream will end soon. Perhaps it did today? We'll have to wait and see. Anyway a share price often rises in stages after good news and over a period of a few weeks, in line with Elliot Wave Theory. In other words you get a sharp rise (the 1st wave) as happened today on AIM, followed by a fall back on profit taking, before the next rise up (2nd wave) begins. We shall see.
papillon: Don't forget, charlie_munger that buying (or continuing to hold) AMYT at the moment is a gamble on the EASE phase 3 results. What the odds on success are we can only guess at the moment. I like to think it's better than 50/50, but who knows? No one! Whatever the odds the upside will be much greater than the downside. Last years merger with Aegerion which gave AMYT a US$150m+ revenue stream, entailing the exchange of a chunk of Aegerion's debt for new AMYT shares, the placing leaving AMYT with US$60m of cash and the issue of the vouchers (that could be worth up to US$85m) to old AMYT shareholders already on the share register when the merger was completed (as compensation for losing their sole rights to AP101) has meant the downside to the AMYT share price could be very marginal if AP101 proves to be useless. However I don't believe that any upside is currently factored into the AMYT share price if AP101 proves successful (unlike with FARN over 2 years ago). In fact I think selling by nervous holders, allied with a lack of buyers, pending the outcome of the EASE phase 3 results is having a depressing effect on the AMYT share price Whatever, I'm continuing to hold and might have another small top up. That wouldn't be the case if the merger with Aegerion hadn't taken place. If that merger hadn't occurred then an AP101 failure would have decimated the AMYT share price and the risk would have been too high for me to hold more than say a grand's worth! The converse is, the upside would have been much, much, greater on a successful outcome to the EASE trial.
papillon: They're probably waiting for these EASE phase3 results, Nick, before shelling out with more of their money. Not long to wait now before we see the direction the AMYT share price will take. To be honest, Nick, the AMYT share price rose significantly from early May until early July precisely because of the imminent listing on Nasdaq and I suspect a large chunk of the buying on AIM during that time was by American investors. Definitely the very large trades during that time were likely made by Americans. Don't forget they have around 70% of AMYT shares. They have seen big gains (sp doubled in 2 months), some, no doubt, took some profits off the table and are waiting before buying back in (or selling the lot if the trial news is bad!). At the moment if you buy, or hold, AMYT shares you are taking a punt on that EASE trial result. I firmly believe the percentage rise in the share price if the news is positive will be far greater than the percentage drop if the news is negative, but the direction of the AMYT share price will definitely depend on that news. We could get a speculative rise in the share price preceding the news, but I'm only guessing. PS There are biotechs listed on Nasdaq with less turnover than AMYT and loss making with much higher Mkt Caps than AMYT. Sp's and hence Mkt Caps of biotechs on Nasdaq all depend on how investors view the company prospects and not necessarily whether they are currently making a profit, Nick.
ultrasharp: The AMYT share price almost doubled from the start of May, 74tom, partly on the back of the expected listing on Nasdaq. There's an old stock market adage, 74tom and that's buy on the prospect of good news and sell on that news becoming fact. Definitely the case here. ATB PAPILLON PS I bought back 1000 shares this afternoon. The price to buy was just over 178p. PPS AMYT has twice raised capital and both times the share price fell so I don't understand your "damp squid" and lack of capital raise comment. Also it's been known for some time that there would be no capital raise linked to the Nasdaq listing yet still the share price rose!!
Amryt Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210121 03:16:09